- Predictive
Oncology Inc. harnessing the power of artificial intelligence and its rich
database of tumor data to help clinicians match cancer patients with most
effective drug treatments
- Like
Amazon’s customer dataset, POAI’s deep database of historical tumor
information positions it for industry success
- Precision
medicine is a data problem – demonstrates the huge value of data and those
companies that generate it
When shopping on Amazon, it seems like the multinational
technology company knows its customers intimately. Every product filtered into
a search query response seems carefully curated to match each customer. This
ability to leverage big data has pushed Amazon to the peak of success, and it
now accounts for approximately 50 percent of all purchases made online (http://ibn.fm/0s6Qw).
Amazon’s success is a result of the company’s deep
historical dataset of customer purchase profiles and its ability to leverage
that with technologies such as AI. Across multiple industries from e-commerce,
through finance to health care, there is now a recognition that data and the
algorithms that help make sense of data are increasingly valuable and a key
competitive differentiator.
From the health care field Predictive
Oncology Inc. (NASDAQ: POAI) has been garnering industry attention as
a hidden gem in the field of precision medicine for its innovative use of data
and algorithms.
Precision Oncology is harnessing the power of artificial
intelligence (think algorithms) to revolutionize treatment outcomes for cancer
patients. What sets POAI apart from its competitors is the same factor that
fueled Amazon’s rise: data. POAI (via its Helomics acquisition) has a huge
proprietary database of tumor information, gathered from over 15+ years of
clinical testing, which uniquely contains the drug responses of 150,000
individual patient tumors. Like Amazon’s database, which grows with each
purchase, this unique tumor database grows daily as new tumors are tested.
While the use of data in cancer diagnostics is becoming more
commonplace (think BRCA gene testing for breast cancer), for most patients the
genomic data gathered from their tumor is not actionable, because researchers
have a poor understanding of what mutations are important for choosing therapy.
In the Amazon example, it would be like knowing people purchased dog food and
cat litter but failing to predict they should buy cat food. POAI’s unique data
on tumor drug response builds AI-driven predictive models that bring together
the mutational and drug response profiles of the tumor to offer true actionable
insights.
POAI is working with the pharmaceutical, diagnostic, and
biotech industries to use its predictive models to both improve the development
of new drugs (patients of tomorrow) as well as help clinicians individualize
therapy (patients of today).
One disruptive aspect of POAI’s technology is that it helps
the clinician to increase the chance of choosing more effective therapy,
resulting in potential reduction of side-effects as well as cost savings.
Traditionally oncologists prescribe what drugs they think have the best chance
at beating a patient’s cancer, and the drug may or may not prove effective.
Meanwhile, the patient’s undergoes chemotherapy with often debilitating side
effects. If the drug proves to be a poor fit for the patient’s cancer, the
chemotherapy experience will have been in vain, and the patient must continue
acting as a guinea pig in experimenting with the next likely drug candidate.
This is the standard cancer treatment of today. However, by utilizing POAI’s
innovative tumor-profiling platform, which literally performs chemotherapy on the
patient’s tumor outside the body to determine which drug is most effective, the
patient can be spared many of the risks of being a “guinea-pig” as the
oncologist attempts different drugs.
As Predictive leverages the data from its huge database of
150,000 of these “chemo outside the body” tests to build new predictive models,
the ability to help the clinician choose the most effective drug for a patient
cancer will improve. In addition, Predictive’s valuable predictive model will
be a boon to the pharmaceutical industry in their race to develop new drugs to
fight cancer.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
